WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹173 Cr | ₹99 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹173 Cr |
| Mar2024 | ₹99 Cr |
| Mar2023 | ₹11 Cr |
| Mar2022 | ₹11 Cr |
| Mar2021 | ₹84 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹173 Cr | 74.78 | |
| Mar2024 | ₹99 Cr | 815.56 | |
| Mar2023 | ₹11 Cr | 2.34 | |
| Mar2022 | ₹11 Cr | -87.49 | |
| Mar2021 | ₹84 Cr | - | |
Compare Total Non-Current Liabilities of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹1,176.0 Cr | -2.1% | 26.4% | 22.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,786.0 Cr | 0.5% | 6.8% | 16.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,590.0 Cr | 0.6% | 8.7% | 7.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,658.0 Cr | 0.4% | 13.8% | 46.9% | Stock Analytics | |
| CIPLA | ₹115,728.0 Cr | -0.4% | 5.8% | -2.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,708.0 Cr | -1.9% | -5.1% | -2.2% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -2.1% |
26.4% |
22.8% |
| SENSEX | 0.5% |
0.1% |
-6.1% |
You may also like the below Video Courses